Telmisartan Is a Promising Agent for Managing Neuropathic Pain and Delaying Opioid Analgesic Tolerance in Rats

Karádi, Dávid Árpád and Galambos, Anna Rita and Lakatos, Péter Pál and Apenberg, Joost and Abbood, Sarah Kadhim and Balogh, Mihály and Király, Kornél P and Riba, Pál and Essmat, Nariman and Szűcs, Edina and Benyhe, Sándor and Varga, Zoltán and Szökő, Éva and Tábi, Tamás and Al-Khrasani, Mahmoud (2023) Telmisartan Is a Promising Agent for Managing Neuropathic Pain and Delaying Opioid Analgesic Tolerance in Rats. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (9). No-7970. ISSN 1661-6596

Preview

Text ijms-24-07970-v2.pdf - Published Version Available under License Creative Commons Attribution. Download (32MB) | Preview

Abstract

Despite the large arsenal of analgesic medications, neuropathic pain (NP) management is not solved yet. Angiotensin II receptor type 1 (AT1) has been identified as a potential target in NP therapy. Here, we investigate the antiallodynic effect of AT1 blockers telmisartan and losartan, and particularly their combination with morphine on rat mononeuropathic pain following acute or chronic oral administration. The impact of telmisartan on morphine analgesic tolerance was also assessed using the rat tail-flick assay. Morphine potency and efficacy in spinal cord samples of treated neuropathic animals were assessed by [35S]GTPγS-binding assay. Finally, the glutamate content of the cerebrospinal fluid (CSF) was measured by capillary electrophoresis. Oral telmisartan or losartan in higher doses showed an acute antiallodynic effect. In the chronic treatment study, the combination of subanalgesic doses of telmisartan and morphine ameliorated allodynia and resulted in a leftward shift in the dose–response curve of morphine in the [35S]GTPγS binding assay and increased CSF glutamate content. Telmisartan delayed morphine analgesic-tolerance development. Our study has identified a promising combination therapy composed of telmisartan and morphine for NP and opioid tolerance. Since telmisartan is an inhibitor of AT1 and activator of PPAR-γ, future studies are needed to analyze the effect of each component.

Actions (login required)

Edit Item